Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study

Abstract Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune bioma...

Full description

Bibliographic Details
Main Authors: Victor Sarradin, Amélie Lusque, Thomas Filleron, Florence Dalenc, Camille Franchet
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Breast Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13058-021-01437-4
id doaj-1e4648556cd94fd8825881faa3eb2701
record_format Article
spelling doaj-1e4648556cd94fd8825881faa3eb27012021-05-30T11:32:58ZengBMCBreast Cancer Research1465-542X2021-05-0123111110.1186/s13058-021-01437-4Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 studyVictor Sarradin0Amélie Lusque1Thomas Filleron2Florence Dalenc3Camille Franchet4Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Biostatistics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Biostatistics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleAbstract Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune biomarkers. Methods Tumor-infiltrating lymphocytes (TILs) were identified from hematoxylin-eosin-stained sections of paired pre- and post-NACT tumor samples from a TNBC cohort (n = 66) and expression of PD-L1, TIM-3, and LAG-3 evaluated by immunohistochemistry. Results Overall TIL counts and PD-L1 expression did not differ pre- and post-NACT, but there was a response-specific statistically significant difference. TIL counts decreased in 65.5% of patients who achieved a pathological complete response (pCR) and increased in 56.8% of no-pCR patients (p = 0.0092). PD-L1 expression was significantly more frequently lost after NACT in pCR than in no-pCR patients (41.4% vs 16.2%, p = 0.0020). TIM-3 positivity (≥ 1%) was significantly more frequent after NACT (p < 0.0001) with increases in expression levels occurring more frequently in no-pCR than in pCR patients (51.4% vs 31%). LAG-3 expression significantly decreased after NACT, but there was no difference between response groups. Before NACT, a high TIL count (> 10%) was significantly associated with better overall survival (OS), p = 0.0112. After NACT, PD-L1 positivity and strong TIM-3 positivity (≥ 5%) were both associated with significantly worse OS (p = 0.0055 and p = 0.0274, respectively). Patients positive for both PD-L1 and TIM-3 had the worst prognosis (p = 0.0020), even when only considering patients who failed to achieve a pCR, p = 0.0479. Conclusions NACT induces significant IME changes in TNBCs. PD-L1 and TIM-3 expression post-NACT may yield important prognostic information for TNBC patients.https://doi.org/10.1186/s13058-021-01437-4Triple-negative breast cancerNeoadjuvant chemotherapyImmune microenvironmentTumor-infiltrating lymphocytesTILsPD-L1
collection DOAJ
language English
format Article
sources DOAJ
author Victor Sarradin
Amélie Lusque
Thomas Filleron
Florence Dalenc
Camille Franchet
spellingShingle Victor Sarradin
Amélie Lusque
Thomas Filleron
Florence Dalenc
Camille Franchet
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Breast Cancer Research
Triple-negative breast cancer
Neoadjuvant chemotherapy
Immune microenvironment
Tumor-infiltrating lymphocytes
TILs
PD-L1
author_facet Victor Sarradin
Amélie Lusque
Thomas Filleron
Florence Dalenc
Camille Franchet
author_sort Victor Sarradin
title Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_short Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_full Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_fullStr Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_full_unstemmed Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_sort immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the mimosa-1 study
publisher BMC
series Breast Cancer Research
issn 1465-542X
publishDate 2021-05-01
description Abstract Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune biomarkers. Methods Tumor-infiltrating lymphocytes (TILs) were identified from hematoxylin-eosin-stained sections of paired pre- and post-NACT tumor samples from a TNBC cohort (n = 66) and expression of PD-L1, TIM-3, and LAG-3 evaluated by immunohistochemistry. Results Overall TIL counts and PD-L1 expression did not differ pre- and post-NACT, but there was a response-specific statistically significant difference. TIL counts decreased in 65.5% of patients who achieved a pathological complete response (pCR) and increased in 56.8% of no-pCR patients (p = 0.0092). PD-L1 expression was significantly more frequently lost after NACT in pCR than in no-pCR patients (41.4% vs 16.2%, p = 0.0020). TIM-3 positivity (≥ 1%) was significantly more frequent after NACT (p < 0.0001) with increases in expression levels occurring more frequently in no-pCR than in pCR patients (51.4% vs 31%). LAG-3 expression significantly decreased after NACT, but there was no difference between response groups. Before NACT, a high TIL count (> 10%) was significantly associated with better overall survival (OS), p = 0.0112. After NACT, PD-L1 positivity and strong TIM-3 positivity (≥ 5%) were both associated with significantly worse OS (p = 0.0055 and p = 0.0274, respectively). Patients positive for both PD-L1 and TIM-3 had the worst prognosis (p = 0.0020), even when only considering patients who failed to achieve a pCR, p = 0.0479. Conclusions NACT induces significant IME changes in TNBCs. PD-L1 and TIM-3 expression post-NACT may yield important prognostic information for TNBC patients.
topic Triple-negative breast cancer
Neoadjuvant chemotherapy
Immune microenvironment
Tumor-infiltrating lymphocytes
TILs
PD-L1
url https://doi.org/10.1186/s13058-021-01437-4
work_keys_str_mv AT victorsarradin immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT amelielusque immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT thomasfilleron immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT florencedalenc immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT camillefranchet immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
_version_ 1721420227607003136